Oncternal Therapeutics Inc. (ONCT)
$0.53
$0.00 (0.00%)As on 29-Apr-2025 09:30EDT
Market cap
$2 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-11.7
-
Face value
--
-
Shares outstanding
2,959,640
10 Years Aggregate
CFO
$-262.08 Mln
EBITDA
$-299.85 Mln
Net Profit
$-291.99 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oncternal Therapeutics (ONCT)
| 0.0 | 0.0 | 0.0 | -93.6 | -69.2 | -60.1 | -53.2 |
|
BSE Sensex*
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Oncternal Therapeutics (ONCT)
| -95.1 | -46.0 | -55.9 | -53.7 | 24.1 | -27.7 | -93.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oncternal Therapeutics (ONCT)
|
0.5 | 1.6 | 1.7 | -34.6 | -3,246.1 | -215.6 | -- | 0.2 |
| 2.7 | 77.7 | 0.0 | -49.0 | -- | -63 | -- | 35.6 | |
| 0.0 | 7.9 | 8.1 | -73.1 | -703.2 | -276.4 | -- | 0.2 |
Shareholding Pattern
View DetailsAbout Oncternal Therapeutics (ONCT)
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal... antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. Read more
-
President, CEO & Director
Dr. James B. Breitmeyer M.D., Ph.D.
-
President, CEO & Director
Dr. James B. Breitmeyer M.D., Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Oncternal Therapeutics (ONCT)
What is the current share price of Oncternal Therapeutics Inc (ONCT) Today?
The share price of Oncternal Therapeutics Inc (ONCT) is $0.53 (NASDAQ) as of 29-Apr-2025 09:30 EDT. Oncternal Therapeutics Inc (ONCT) has given a return of -69.19% in the last 3 years.
What is the current PB & PE ratio of Oncternal Therapeutics Inc (ONCT)?
Since, TTM earnings of Oncternal Therapeutics Inc (ONCT) is negative, P/E ratio is not available.
The P/B ratio of Oncternal Therapeutics Inc (ONCT) is 0.17 times as on 29-Apr-2025, a 97 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.04 |
0.05 |
2022 |
-0.07 |
-0.02 |
2021 |
-3.58 |
-0.98 |
2020 |
-8.37 |
-1.74 |
2019 |
-3.81 |
4.24 |
What is the 52 Week High and Low of Oncternal Therapeutics Inc (ONCT)?
The 52-week high and low of Oncternal Therapeutics Inc (ONCT) are Rs -- and Rs -- as of 28-Aug-2026.
What is the market cap of Oncternal Therapeutics Inc (ONCT)?
Oncternal Therapeutics Inc (ONCT) has a market capitalisation of $ 2 Mln as on 29-Apr-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Oncternal Therapeutics Inc (ONCT)?
Before investing in Oncternal Therapeutics Inc (ONCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.